Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan

Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan
  • Daiichi Sankyo Co Ltd DSNKY said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason.
  • However, the Nikkei newspaper reported that there were safety concerns.
  • In March, the company started a Phase 1 trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients.
  • Nafamostat is used in the treatment of pancreatitis and has antiviral properties.
  • Price Action: DSNKY closed at $23.76 on Monday.
Posted In: BriefsCovid-19COVID-19 VaccineBiotechNewsHealth CareGeneral